CIBC Asset Management’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$27.8M Buy
71,829
+13,113
+22% +$4.86M 0.06% 212
2026
Q1
$17.2M Sell
58,716
-286
-0.5% -$94K 0.04% 284
2025
Q4
$20.7M Buy
59,002
+24,928
+73% +$8.42M 0.05% 243
2025
Q3
$11M Sell
34,074
-8,591
-20% -$2.67M 0.03% 290
2025
Q2
$16.6M Sell
42,665
-2,786
-6% -$1.12M 0.05% 229
2025
Q1
$19.8M Buy
45,451
+4,516
+11% +$1.81M 0.07% 198
2024
Q4
$15.1M Buy
40,935
+6,923
+20% +$2.9M 0.05% 218
2024
Q3
$17.7M Buy
34,012
+2,541
+8% +$1.36M 0.06% 197
2024
Q2
$17.1M Sell
31,471
-1,955
-6% -$1.03M 0.06% 189
2024
Q1
$17.3M Buy
33,426
+1,008
+3% +$501K 0.06% 196
2023
Q4
$15.3M Sell
32,418
-1,630
-5% -$754K 0.06% 195
2023
Q3
$14.8M Sell
34,048
-862
-2% -$391K 0.06% 186
2023
Q2
$15.5M Sell
34,910
-385
-1% -$178K 0.06% 184
2023
Q1
$16.2M Buy
35,295
+712
+2% +$339K 0.06% 179
2022
Q4
$17.7M Buy
34,583
+2,097
+6% +$1.06M 0.07% 164
2022
Q3
$14.8M Buy
32,486
+2,665
+9% +$1.28M 0.06% 172
2022
Q2
$14.4M Buy
29,821
+1,847
+7% +$914K 0.06% 174
2022
Q1
$13.7M Buy
27,974
+4,799
+21% +$2.19M 0.05% 194
2021
Q4
$10.7M Buy
23,175
+1,002
+5% +$422K 0.04% 233
2021
Q3
$8.27M Buy
22,173
+528
+2% +$201K 0.03% 264
2021
Q2
$8.26M Buy
21,645
+193
+0.9% +$73.8K 0.03% 266
2021
Q1
$7.7M Sell
21,452
-1,026
-5% -$330K 0.03% 264
2020
Q4
$7.22M Sell
22,478
-62
-0.3% -$19K 0.03% 261
2020
Q3
$6.05M Buy
22,540
+293
+1% +$78.8K 0.03% 256
2020
Q2
$5.85M Sell
22,247
-1,732
-7% -$462K 0.03% 242
2020
Q1
$5.44M Sell
23,979
-3,065
-11% -$835K 0.04% 233
2019
Q4
$8.17M Sell
27,044
-1,350
-5% -$372K 0.05% 179
2019
Q3
$6.82M Buy
28,394
+2,408
+9% +$660K 0.04% 198
2019
Q2
$7.33M Buy
25,986
+2,607
+11% +$712K 0.04% 184
2019
Q1
$6.71M Sell
23,379
-11,974
-34% -$3.46M 0.04% 192
2018
Q4
$9.29M Sell
35,353
-30,397
-46% -$8.36M 0.07% 122
2018
Q3
$18M Sell
65,750
-319
-0.5% -$82.8K 0.11% 88
2018
Q2
$15.7M Buy
66,069
+41,813
+172% +$9.68M 0.1% 95
2018
Q1
$5.33M Sell
24,256
-1,383
-5% -$325K 0.03% 208
2017
Q4
$5.77M Sell
25,639
-311
-1% -$66.2K 0.04% 198
2017
Q3
$4.93M Buy
25,950
+654
+3% +$124K 0.03% 220
2017
Q2
$4.76M Buy
25,296
+97
+0.4% +$17.4K 0.03% 216
2017
Q1
$4.17M Sell
25,199
-118
-0.5% -$18.8K 0.03% 241
2016
Q4
$3.64M Buy
25,317
+440
+2% +$58.9K 0.03% 254
2016
Q3
$3.12M Sell
24,877
-2,103
-8% -$272K 0.02% 292
2016
Q2
$3.54M Buy
26,980
+575
+2% +$78.7K 0.03% 256
2016
Q1
$3.67M Buy
26,405
+144
+0.5% +$19.2K 0.03% 243
2015
Q4
$3.66M Sell
26,261
-2,825
-10% -$389K 0.03% 233
2015
Q3
$4.07M Buy
29,086
+122
+0.4% +$18.3K 0.03% 209
2015
Q2
$4.75M Buy
28,964
+765
+3% +$122K 0.03% 212
2015
Q1
$4.35M Sell
28,199
-1,627
-5% -$232K 0.03% 216
2014
Q4
$3.75M Sell
29,826
-5,393
-15% -$666K 0.03% 235
2014
Q3
$4.21M Sell
35,219
-830
-2% -$95.2K 0.03% 238
2014
Q2
$3.88M Sell
36,049
-391
-1% -$40.3K 0.02% 259
2014
Q1
$3.63M Sell
36,440
-11,330
-24% -$1.02M 0.02% 272
2013
Q4
$4.41M Sell
47,770
-3,760
-7% -$334K 0.03% 237
2013
Q3
$4.31M Buy
51,530
+1,100
+2% +$94.3K 0.03% 229
2013
Q2
$4.13M Buy
+50,430
New +$3.77M 0.03% 227

Other funds holding ELV

CIBC Asset Management's ELV Position: Q2 2026 in Review

CIBC Asset Management increased its Elevance Health (ELV) stake by 22% in Q2 2026, buying an estimated $4.86M and bringing the position to 71,829 shares worth $27.8M. The position accounts for 0.06% of the portfolio, ranked #212.

CIBC Asset Management first reported a position in ELV in Q2 2013 and has held it in 53 quarters since. 1,602 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • CIBC Asset Management held 71,829 shares of Elevance Health worth $27.8M as of Q2 2026.
  • CIBC Asset Management bought 13,113 Elevance Health shares in Q2 2026, an estimated $4.86M.
  • Elevance Health made up 0.06% of CIBC Asset Management's portfolio in Q2 2026, its #212 holding.
  • CIBC Asset Management first reported a position in Elevance Health in Q2 2013 and has held it in 53 quarters since.
  • 1,602 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.